ROCKVILLE, Md.--(BUSINESS WIRE)--GenArraytion, Inc. announced today that it self-funded the development of the first commercially available polymerase chain reaction (PCR)-based molecular test to identify the Zika virus, a fever-causing disease transmitted by the Aedes aegypti mosquito. The Zika virus test works with an existing GenArraytion MultiFLEX™ Bioassay panel that targets viruses causing dengue fever, yellow fever and Chikungunya, which are also carried by this mosquito and are known to cause febrile disease in humans.
